There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Phio Pharmaceuticals (PHIO – Research Report), Theravance Biopharma (TBPH – Research Report) and CymaBay Therapeutics (CBAY – Research Report) with bullish sentiments. Phio Pharmaceuticals (PHIO) In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Phio Pharmaceuticals, with a price target of $6.00. The company's shares closed last Monday at $0.92, close to its 52-week low of $0.70. According to TipRanks.
https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-122?utm_source=advfn.com&utm_medium=referral
Theravance Biopharma (NASDAQ:TBPH)
Historical Stock Chart
From Aug 2022 to Sep 2022 Click Here for more Theravance Biopharma Charts.
Theravance Biopharma (NASDAQ:TBPH)
Historical Stock Chart
From Sep 2021 to Sep 2022 Click Here for more Theravance Biopharma Charts.